Abstract:Self-amplifying replicon RNA (RepRNA) promotes expansion of mRNA templates encoding genes of interest through their replicative nature, thus providing increased antigen payloads. RepRNA derived from the non-cytopathogenic classical swine fever virus (CSFV) targets monocytes and dendritic cells (DCs), potentially promoting prolonged antigen expression in the DCs, contrasting with cytopathogenic RepRNA. We engineered pestivirus RepRNA constructs encoding influenza virus H5N1 (A/chicken/Yamaguchi/7/2004) nucleoprotein (Rep-NP) or hemagglutinin (Rep-HA). The inherent RNase-sensitivity of RepRNA had to be circumvented to ensure efficient delivery to DCs for intracellular release and RepRNA translation; we have reported how only particular synthetic delivery vehicle formulations are appropriate. The question remained concerning RepRNA packaged in virus replicon particles (VRPs); we have now compared an efficient polyethylenimine (PEI)-based formulation (polyplex) with VRP-delivery as well as naked RepRNA co-administered with the potent bis-(3',5')-cyclic dimeric adenosine monophosphate (c-di-AMP) adjuvant. All formulations contained a Rep-HA/Rep-NP mix, to assess the breadth of both humoral and cell-mediated defences against the influenza virus antigens. Assessment employed pigs for their close immunological relationship to humans, and as natural hosts for influenza virus. Animals receiving the VRPs, as well as PEI-delivered RepRNA, displayed strong humoral and cellular responses against both HA and NP, but with VRPs proving to be more efficacious. In contrast, naked RepRNA plus c-di-AMP could induce only low-level immune responses, in one out of five pigs. In conclusion, RepRNA encoding different influenza virus antigens are efficacious for inducing both humoral and cellular immune defences in pigs. Comparisons showed that packaging within VRP remains the most efficacious for delivery leading to induction of immune defences; however, this technology necessitates employment of expensive complementing cell cultures, and VRPs do not target human cells. Therefore, choosing the appropriate synthetic delivery vehicle still offers potential for rapid vaccine design, particularly in the context of the current coronavirus pandemic.

Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human-avian influenza (H5N1).

Expression of H5N1 influenza virus hemagglutinin protein fused with protein transduction domain in an alphavirus replicon system.

Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection

A Recombinant Protein Containing Highly Conserved Hemagglutinin Residues 81-122 of Influenza H5N1 Induces Strong Humoral and Mucosal Immune Responses.

[Construction and Immunogenicity Study of DNA Vaccine Expressing Human H5N1 Influenza Virus Hemagglutinin].

[Construction of Bicistronic Eukaryotic Expression Vector Containing HA and M2 Genes Derived from High Pathogenic Avian Influenza Virus (HPAI) H5N1 (anhui Strain)and Its Efficient Expression in Mammalian Cells].

Comparative Immunogenicity of Recombinant Adenovirus-Vectored Vaccines Expressing Different Forms of Hemagglutinin (HA) Proteins from the H5 Serotype of Influenza A Viruses in Mice.

Influenza Viral Vectors Expressing Two Kinds of HA Proteins As Bivalent Vaccine Against Highly Pathogenic Avian Influenza Viruses of Clade 2.3.4.4 H5 and H7N9

A replication-deficient H9N2 influenza virus carrying H5 hemagglutinin conferred protection against H9N2 and H5N1 influenza viruses in mice

Influenza viral vectors expressing two kinds of HA proteins for bivalent vaccines against clade 2.3.4.4 and clade 2.3.2.1 H5 HPAIVs

Intranasal Vaccination Of Recombinant H5n1 Ha1 Proteins Fused With Foldon And Fc Induces Strong Mucosal Immune Responses With Neutralizing Activity: Implication For Developing Novel Mucosal Influenza Vaccines

[Construction of Recombinant Fowlpox Virus Coexpressing HA Gene from H5N1 Avian Influenza Virus and Chicken Interleukin-2 Gene and Assessment of Its Protective Efficacy].

Virus-Like Particle Vaccine Induces Protective Immunity Against Homologous and Heterologous Strains of Influenza Virus

A Replicating Modified Vaccinia Tiantan Strain Expressing an Avian-Derived Influenza H5N1 Hemagglutinin Induce Broadly Neutralizing Antibodies and Cross-Clade Protective Immunity in Mice.

Effectively Evaluating a Novel Consensus Subunit Vaccine Candidate to Prevent the H9N2 Avian Influenza Virus

Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice

Self-Amplifying Pestivirus Replicon RNA Encoding Influenza Virus Nucleoprotein and Hemagglutinin Promote Humoral and Cellular Immune Responses in Pigs

[Construction of a recombinant HVT virus expressing the HA gene of avian influenza virus H5N1 via Rde/ET recombination system]

[Immunological Evaluation of Vector-Expressed M2 and HA Genes of H5N1 Influenza Virus in Mice].

Construction and Immunogenicity of Highly Pathogenic Human-Avian Influenza H5N1 Virus DNA Vaccine

A Recombinant H7N9 Influenza Vaccine with the H7 Hemagglutinin Transmembrane Domain Replaced by the H3 Domain Induces Increased Cross-Reactive Antibodies and Improved Interclade Protection in Mice.